Immunotherapy and patients treated for cancer with microsatellite instability
详细信息 查看全文
- 作者：Raphaë ; l Colle1 ; 7 ; Romain Cohen1 ; 2 ; 3 ; 7 ; Delphine Cochereau1 ; 3 ; Alex Duval2 ; 3 ; Olivier Lascols4 ; Daniel Lopez-Trabada1 ; Pauline Afchain1 ; Isabelle Trouilloud1 ; Yann Parc2 ; 3 ; 5 ; Jé ; ré ; mie H. Lefevre2 ; 3 ; 5 ; Jean-Franç ; ois Flé ; jou2 ; 3 ; 6 ; Magali Svrcek2 ; 3 ; 6 ; Thierry André ; 1 ; 2 ; 3 ; thierry.andre@aphp.fr
- 关键词：Mismatch repair deficiency ; Lynch syndrome ; Immune checkpoint ; Nivolumab ; Endometrial cancer ; Colorectal cancer
- 刊名：Bulletin du Cancer
- 出版年：2017
- 出版时间：January 2017
- 年：2017
- 卷：104
- 期：1
- 页码：42-51
- 全文大小：987 K
- 卷排序：104
文摘
Microsatellite instability (MSI) is a tumor phenotype linked to somatic or germline (Lynch syndrome) inactivating alterations of DNA mismatch repair genes. A broad spectrum of neoplasms exhibits MSI phenotype, mainly colorectal cancer, endometrial cancer, and gastric cancer. MSI tumors are characterized by dense immune infiltration and high load of tumor neo-antigens. Growing evidence is accumulating on the efficacy of immune checkpoint inhibition for patients treated for MSI solid tumors. We present a comprehensive overview of MSI phenotype, its biological landscape and current diagnostic methods. Then we focus on MSI as a predictive biomarker of response to immune checkpoint inhibition in the context of colorectal cancer and non-colorectal tumors.